Indication

In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on the last therapy.

Medicine details

Medicine name:
isatuximab (Sarclisa)
SMC ID:
SMC2303
Pharmaceutical company
Sanofi-Aventis
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
Q1 2021
SMC meeting date:
Q1 2021
Patient group submission deadline:
02 November 2020